QBiotics appoints new Chair and Deputy Chair
8 December 2022
QBiotics Group Limited (QBiotics) is pleased to announce that current Non-Executive Director, Mr. Andrew Denver, has been appointed as the Chair of the board of the Company and current Non-Executive Director, Dr. Susan Foden has been appointed as Deputy Chair.
Mr. Denver has been a Non-Executive Director of QBiotics since 1 June 2016 (initially appointed to the board of its predecessor company QBiotics Limited). He is a highly experienced company director across biotech and life science industries. He is former Managing Director of Memtec Limited, President Asia for Pall Corporation, Chairman of Universal Biosensors Inc. and Chairman of Speedx Pty Ltd (a molecular diagnostics company). Other than his role as Chairman of QBiotics Group, Mr. Denver is currently a Non-Executive Director of Cochlear Ltd and a member of the Audit & Risk, Medical Science, Technology & Innovation and Nomination Committees of the Cochlear Ltd board, and is also a Non-Executive Director of Vaxxas Pty Ltd.
Dr. Foden commenced as a Non-Executive Director of QBiotics on 14 November 2019 and is currently the Chair of the Remuneration Committee. Dr. Foden has a strong background in pharmaceutical drug development and commercialisation and more than 20 years of experience on the boards of small and medium-size public healthcare companies in the UK, Norway, Germany and Belgium. Recent board positions include Ventura Group plc as Senior Independent Director and Chair of the Remuneration Committee. Currently, Dr. Foden is Executive Chair of Neurocentrx Pharma Ltd, Non-Executive Director and Chair of the Remuneration Committee of Evgen Pharma Plc, an Investment Committee member of CD3, the drug discovery initiative between the European Investment Fund and the University of Leuven, and a trustee of the Roslin Foundation in Edinburgh.
Dr. Victoria Gordon, Managing Director and CEO of QBiotics said of the appointment “My fellow directors and I are delighted that Mr. Denver has accepted the role of Chair and we look forward to continuing to work with him in his new role as we progress our human and veterinary programmes. We are also delighted to welcome Dr. Foden to the role of Deputy Chair. Dr. Foden has extensive experience and a deep understanding of drug development and commercialisation which complements the strong regulatory and governance capabilities of the Chair.”